Zogenix — Technical Presentation (September 2017)
9 slides from Zogenix's technical presentation, Sep 29, 2017
Slide 1: Study 1 Phase 3 Top-Line Results
September 2017 STUDY 1 PHASE 3 TOP-LINE RESULTS Exhibit 99.1
Slide 2: Forward Looking Statement
Forward Looking Statement Zogenix cautions you that statements included in this presentation that are not a description of historical facts are forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "intends," "potential," "suggests," "assuming,
Slide 3: ZX008 Phase 3 Study 1 Top-Line Results
ZX008 Phase 3 Study 1 Top-Line Results Trial met primary endpoint of the change in the mean monthly convulsive seizure frequency Focused on Developing and Commercializing Therapies for Rare CNS Disorders All key secondary endpoints positive and demonstrated statistical significance
Slide 4: Phase 3 Study 1 Design
ZX008 Phase 3 Study 1 Design Maximum Daily Dose of 30mg Screening Open Label Safety Study N = 119 Ages 2 – 18 1:1:1 Randomization Placebo N=40 ZX008 0.8 mg/kg/d N=40 ZX008 0.2 mg/kg/d N=39 6 WEEKS BASELINE OBSERVATION 2 WEEKS TITRATION 12 WEEKS MAINTENANCE Study 1 is a prospective merged analysis of
Slide 5: Study 1 Met Primary Efficacy Endpoint
Study 1 Met Primary Efficacy Endpoint Study 1 met primary endpoint demonstrating ZX008, at a dose of 0.8 mg/kg/day, is superior to placebo as adjunctive therapy in the treatment of Dravet syndrome based on the change in the mean monthly convulsive seizure frequency (p< 0.001) ZX008, at a dose of 0.2
Slide 6: Study 1 Convulsive Seizure Responder Rates
Study 1 Convulsive Seizure Responder Rates p-values calculated vs. placebo p=0.033 p<0.001 P=0.001 P=0.001 PROPORTION OF PATIENTS WHO ACHIEVED ≥50% AND ≥75% REDUCTION IN MEAN MONTHLY CONVULSIVE SEIZURES (2 WK TITRATION + 12 WK MAINTENANCE PERIOD)
Slide 7: Study 1 Longest Seizure Free Interval
Study 1 Longest Seizure Free Interval MEDIAN AND MEAN OF EACH PATIENT’S LONGEST SEIZURE FREE INTERVAL (2 WK TITRATION + 12 WK MAINTENANCE PERIOD) p-values are for combined median values vs. placebo Median Mean Median Mean Median Mean p<0.001 p=0.011
Slide 8: Study 1 Safety
ZX008 Study 1 Safety Placebo (N=40) ZX008 0.2 mg (N=39) ZX008 0.8 mg (N=40) Number of Subjects With at Least One Treatment Emergent Adverse Event (AEs) 26 (65.0%) 37 (94.9%) 38 (95.0%) Number of Subjects With at Least One Serious Treatment Emergent Adverse Event (SAEs) 4 (10.0%) 4 (10.3%) 5 (12.5%)
Slide 9: ZX008 Phase 3 Study 1 Top-Line Results
ZX008 Phase 3 Study 1 Top-Line Results Trial met primary endpoint of the change in the mean monthly convulsive seizure frequency Focused on Developing and Commercializing Therapies for Rare CNS Disorders All key secondary endpoints positive and demonstrated statistical significance